Kaleido Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kaleido Biosciences, Inc.
Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
Why Tessera Believes Its Gene Writing Platform Can Go Way Beyond CRISPR
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.
PureTech’s Failure Leaves Long COVID Treatment Hopes Looking Thin
PureTech’s LYT-100 has failed to show benefit over placebo in long COVID, and raised doubts about how treatable the condition is – in contrast to the drug’s other potential use in idiopathic pulmonary fibrosis.
Immunotherapy Biotech Genocea Closes Down As Sector Slump Deepens
The neoantigen immunotherapy company is a casualty of slow R&D progress and a squeeze on biotech finance – and more firms are in the firing line.
- Drug Delivery
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.